Headed up by a highly experience VC with important biotech experience, Hinge Bio, Inc. is structured to leverage a next-generation platform for the development of a new class of flexible, extendible and cooperatively binding therapeutics and diagnostic: flexible (Flex-Hingeâ¢) antibodies and antibody-like molecules with flexible and extendible nonâpeptidyl hinges that allow for "cooperative two-handed binding". Leveraging proprietary technology to make antibodies âflexibleâ enables superior efficacy, safety and quality. This approach enables the development of therapeutics and diagnostics capable of binding either one disease target with multiple "hands," multiplying the number of molecular contacts on the target, enabling enhanced specificity, or binding different targets with each of its hands, enabling biological syn
